Error in Figure/Table
In the published article, there was an error in Table 1 as published. The mean (SD) for the 1L pembrolizumab + chemotherapy column for CPS<1 should be 18 (16.7), not 18 (6.7) as originally shown. Further, we used the terminology, CPS<1% in the first column and the correct terminology is CPS<1. The corrected Table 1 and its caption appear below.
Table 1
| Characteristic | 1L pembrolizumab (all) (N = 646) | 1L pembrolizumab monotherapy (N = 431) | 1L pembrolizumab + chemotherapy (N = 215) |
|---|---|---|---|
| Age (years) | |||
| Median (95% CI) | 68.0 (66.8–68.3) | 69.0 (68.4–70.2) | 64.0 (62.8–65.3) |
| Median (IQR) | 68.0 (61.0–65.0) | 69.0 (63.0–78.0) | 64.0 (59.0–70.0) |
| Sex | |||
| Male | 500 (77.4) | 330 (76.6) | 170 (79.1) |
| Race | |||
| White | 386 (59.8) | 261 (60.6) | 125 (58.1) |
| Black | 34 (5.3) | 21 (4.9) | 13 (6.0) |
| Asian | 6 (0.9) | 4 (0.9) | 2 (0.9) |
| Other | 220 (34.1) | 145 (33.6) | 75 (34.9) |
| Smoking status A | |||
| History of smoking | 507 (78.5) | 343 (79.6) | 164 (76.3) |
| No history of smoking | 138 (21.4) | 88 (20.4) | 50 (23.3) |
| Census region | |||
| South | 375 (58.0) | 251 (58.2) | 124 (57.7) |
| Midwest | 78 (12.1) | 54 (12.5) | 24 (11.2) |
| West | 67 (10.4) | 37 (8.6) | 30 (14.0) |
| Northeast | 60 (9.3) | 40 (9.3) | 20 (9.3) |
| Unknown/not documented | 66 (10.2) | 49 (11.4) | 17 (7.9) |
| Practice type | |||
| Community | 583 (90.2) | 384 (89.1) | 199 (92.6) |
| Academic | 57 (8.8) | 43 (10.0) | 14 (6.5) |
| Both | 6 (0.9) | 4 (0.9) | 2 (0.9) |
| Primary tumor site(s) | |||
| Oropharynx | 297 (46.0) | 193 (44.8) | 104 (48.4) |
| Larynx | 166 (25.7) | 120 (27.8) | 46 (21.4) |
| Oral cavity | 138 (21.4) | 89 (20.6) | 49 (22.8) |
| Hypopharynx | 35 (5.4) | 23 (5.3) | 12 (5.6) |
| Other B | 10 (1.5) | 6 (1.4) | 4 (1.9) |
| Disease status | |||
| Distant metastatic disease (HNSCC with distant recurrence OR Stage IVc at initial diagnosis) | 367 (56.8) | 238 (55.2) | 129 (60.0) |
| HNSCC with locoregional recurrence C | 149 (23.1) | 106 (24.6) | 43 (20.0) |
| HNSCC not cured at initial diagnosis | 106 (16.4) | 77 (17.9) | 29 (13.5) |
| HPV-positive Stage IV oropharyngeal tumor at initial diagnosis | 24 (3.7) | 10 (2.3) | 14 (6.5) |
| Stage at initial diagnosis | |||
| I–II | 115 (17.8) | 88 (20.4) | 27 (12.6) |
| III–IVB | 326 (50.5) | 232 (53.8) | 94 (43.7) |
| IV | 24 (3.7) | 10 (2.3) | 14 (6.5) |
| IVc | 92 (14.2) | 41 (9.5) | 51 (23.7) |
| Unknown/not documented | 89 (13.8) | 60 (13.9) | 29 (13.5) |
| ECOG PS on index date | |||
| 0–1 | 427 (66.1) | 265 (61.5) | 162 (75.3) |
| 2–4 | 135 (20.9) | 103 (23.9) | 32 (14.9) |
| Unknown/not documented | 84 (13.0) | 63 (14.6) | 21 (9.8) |
| HPV status (all subtypes) | |||
| Positive | 233 (36.1) | 163 (37.8) | 70 (32.6) |
| Negative | 258 (39.9) | 165 (38.3) | 93 (43.3) |
| Equivocal or unknown | 155 (24.0) | 103 (24.9) | 52 (24.2) |
| HPV status (oropharynx subtype only) | N = 297 | N = 193 | N = 104 |
| Positive | 192 (64.6) | 137 (71.0) | 55 (52.9) |
| Negative | 87 (29.3) | 47 (24.4) | 40 (38.5) |
| Equivocal or unknown | 18 (6.1) | 9 (4.7) | 9 (8.7) |
| Evidence of PD-L1 testing D | |||
| Yes | 463 (71.7) | 318 (73.8) | 145 (67.4) |
| CPS E | N = 352 | N = 244 | N = 108 |
| <1 | 36 (10.2) | 18 (7.4) | 18 (16.7) |
| ≥1 | 295 (83.8) | 211 (86.5) | 84 (77.8) |
| ≥20 | 149 (42.3) | 109 (44.7) | 40 (37.0) |
| Unknown/not documented | 21 (6.0) | 15 (6.1) | 6 (5.7) |
Baseline demographic and clinical characteristics of individuals receiving 1L pembrolizumab monotherapy or pembrolizumab plus chemotherapy.
1L, first-line; CI, confidence interval; CPS, combined positive score; ECOG PS, Eastern Cooperative Oncology Group performance status; HNSCC, head and neck squamous cell carcinoma; HPV, human papillomavirus; IQR, interquartile range; PD-L1, programmed death ligand 1.
All values are given as n (%) unless otherwise indicated.
A Smoking status was not documented for 1 individual receiving 1L pembrolizumab + platinum + 5-FU.
B Includes pharynx not otherwise specified, tongue not otherwise specified, or other unspecified tumor site.
C Includes individuals not cured at first locoregional recurrence, or with second locoregional recurrence.
D PD-L1 testing performed at index date ± 30 days.
E If multiple CPS values were available, the score recorded closest to the index date was reported.
In the published article, there was an error in Table 2 as published. We used the terminology CPS (referent: <1%) in column one and the correct terminology is CPS (referent: <1). The corrected Table 2 and its caption appear below.
Table 2
| Variable | OR | 95% CI | p-value |
|---|---|---|---|
| Age (referent: <65 years) | |||
| ≥65 years | 2.42 | 1.68–3.52 | <0.001 |
| Sex (referent: male) | |||
| Female | 1.41 | 0.90–2.22 | 0.140 |
| ECOG PS on index date (referent: 0–1) | |||
| 2–4 | 2.03 | 1.26–3.34 | 0.004 |
| Unknown/not defined | 2.30 | 1.29–4.23 | 0.006 |
| History of smoking (referent: no/unknown) | |||
| Yes | 1.43 | 0.89–2.26 | 0.132 |
| Primary tumor site (referent: oropharynx) | |||
| Hypopharynx | 1.46 | 0.61–3.65 | 0.403 |
| Larynx | 1.84 | 1.09–3.12 | 0.023 |
| Oral cavity | 0.91 | 0.52–1.59 | 0.740 |
| Other A | 0.99 | 0.24–4.43 | 0.998 |
| HPV status (referent: positive) | |||
| Negative | 0.59 | 0.36–0.93 | 0.026 |
| Unknown | 0.58 | 0.32–1.03 | 0.065 |
| CPS (referent: <1) | |||
| 1–19 | 2.62 | 1.12–6.12 | 0.026 |
| ≥20 | 3.21 | 1.37–7.55 | 0.007 |
| Unknown | 1.87 | 0.85–4.09 | 0.117 |
| Census region (referent: Northeast) | |||
| Midwest | 1.31 | 0.59–2.89 | 0.495 |
| South | 0.88 | 0.46–1.64 | 0.704 |
| West | 0.40 | 0.18–0.89 | 0.027 |
| Missing/not defined | 1.16 | 0.50–2.69 | 0.720 |
| Advanced diagnostic criteria (referent: HPV-positive Stage IV oropharyngeal tumor at initial diagnosis) | |||
| HNSCC not cured at initial diagnosis | 4.58 | 2.49–8.61 | <0.001 |
| Distant metastatic disease (HNSCC with distant recurrence OR Stage IVc at initial diagnosis) | 4.83 | 2.90–8.17 | <0.001 |
| HNSCC with locoregional recurrence | 4.62 | 2.61–8.35 | <0.001 |
Factors associated with use of 1L pembrolizumab monotherapy versus pembrolizumab plus chemotherapy: stepwise logistic regression model.
1L, first-line; CI, confidence interval; CPS, combined positive score; ECOG PS, Eastern Cooperative Oncology Group performance status; HNSCC, head and neck squamous cell carcinoma; HPV, human papilloma virus; OR, odds ratio. Statistically significant p-values (<0.05) are presented in bold.
A Includes pharynx not otherwise specified, tongue not otherwise specified, or other unspecified tumor site.
Text Correction
In the published article, there was an error to the text in Results, Study population, where "CPS<1" was referred to as "CPS<1%".
This sentence previously stated: “A CPS of <1% was recorded for 10.2% of this latter group, while 83.8% had a score of ≥1 and 42.3% had a score of ≥20.”
The corrected sentence appears below:
“A CPS of <1 was recorded for 10.2% of this latter group, while 83.8% had a score of ≥1 and 42.3% had a score of ≥20.”
The authors apologize for these errors and state that these does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
head and neck squamous cell carcinoma, antineoplastic agents, immunological, antibodies, Kaplan-Meier estimate, patient outcomes, real-world observational study, treatment patterns
Citation
Black CM, Hanna GJ, Wang L, Ramakrishnan K, Goto D, Turzhitsky V and Hair GM (2023) Corrigendum: Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma. Front. Oncol. 13:1240947. doi: 10.3389/fonc.2023.1240947
Received
17 June 2023
Accepted
30 June 2023
Published
17 July 2023
Volume
13 - 2023
Edited and reviewed by
Fernanda Visioli, Federal University of Rio Grande do Sul, Brazil
Updates
Copyright
© 2023 Black, Hanna, Wang, Ramakrishnan, Goto, Turzhitsky and Hair.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Christopher M. Black, Christopher.black2@merck.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.